Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020;578:527–39.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ng SC, Shi HY, Hamidi N, Underwood F, Tang W, Benchimol E, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.

PubMed  Article  Google Scholar 

Kobayashi T, Siegmund B, Le Berre C, Wei S, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis primers. 2020;6:74.

PubMed  Article  Google Scholar 

Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018;3:790–802.

PubMed  Article  Google Scholar 

de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–49.

PubMed  Article  Google Scholar 

Ananthakrishnan AN, Bernstein C, Iliopoulos D, Macpherson A, Neurath M, Ali R, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15:39–49.

PubMed  Article  Google Scholar 

Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652–64.

CAS  PubMed  Article  Google Scholar 

Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol. 2015;1:154–70.

PubMed  PubMed Central  Article  Google Scholar 

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702.

CAS  PubMed  Article  Google Scholar 

Cooper HS, Murthy S, Shah R, Sedergran D. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238–49.

CAS  PubMed  Google Scholar 

Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014;104:15.25.11–15.25.14.

Google Scholar 

Huang B, Chen Z, Geng L, Wang J, Liang H, Cao Y, et al. Mucosal profiling of pediatric-onset colitis and IBD reveals common pathogenics and therapeutic pathways. Cell. 2019;179:1160–76.

CAS  PubMed  Article  Google Scholar 

Pandey A, Shen C, Feng S, Man SM. Cell biology of inflammasome activation. Trends Cell Biol. 2021;31:924–39.

CAS  PubMed  Article  Google Scholar 

Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–20.

CAS  PubMed  Article  Google Scholar 

Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. 2018;17:688.

CAS  PubMed  Article  Google Scholar 

Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, et al. Inflammasomes as therapeutic targets in human diseases. Signal Transduct Target Ther. 2021;6:247.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Zhen Y & Zhang H, NLRP3 Inflammasome and inflammatory bowel disease. Front Immunol. 2019;10:276.

Villani AC, Lemire M, Fortin G, Louis E, Silverberg M, Collette C, et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat Genet. 2009;41:71–76.

CAS  PubMed  Article  Google Scholar 

Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59:1192–9.

CAS  PubMed  Article  Google Scholar 

Neudecker V, Haneklaus M, Jensen O, Khailova L, Masterson JC, Tye H, et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J Exp Med. 2017;214:1737–52.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8:8618.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Cosin-Roger J, Simmen S, Melhem H, Atrott K, Frey-Wagner I, Hausmann M, et al. Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. Nat Commun. 2017;8:98.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Mao L, Kitani A, Hiejima E, Montgomery-Recht K, Zhou W, Fuss I, et al. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis. J Clin Invest. 2020;130:1793–807.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207:1045–56.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379–91.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rühl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol. 2015;45:2927–36.

PubMed  Article  CAS  Google Scholar 

He Y, Zeng MY, Yang D, Motro B, Núñez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530:354–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Di A, Xiong S, Ye Z, Malireddi RKS, Kometani S, Zhong M, et al. The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation. Immunity. 2018;49:56–65.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ye J, Zeng B, Zhong M, Li H, Xu L, Shu J, et al. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling. Acta Pharm Sin B. 2021;11:112–26.

CAS  PubMed  Article  Google Scholar 

Zhong CS, Zeng B, Qiu JH, Xu LH, Zhong MY, Huang YT, et al. Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways. Acta Pharmacol Sin. 2021;43:1324–36.

PubMed  Article  CAS  Google Scholar 

Shu JX, Zhong C, Shi Z, Zeng B, Xu L, Ye J, et al. Berberine augments hypertrophy of colonic patches in mice with intraperitoneal bacterial infection. Int Immunopharmacol. 2021;90:107242.

CAS  PubMed  Article  Google Scholar 

Liu L, Li X. NLRP3 inflammasome in inflammatory bowel disease: friend or foe? Dig Dis Sci. 2017;62:2211–4.

PubMed  Article  Google Scholar 

Bauer C, Duewell P, Lehr H, Endres S, Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis. 2012;30:82–90.

PubMed  Article  Google Scholar 

Hara H, Seregin S, Yang D, Fukase K, Chamaillard M, Alnemri E, et al. The NLRP6 inflammasome recognizes lipoteichoic acid and regulates gram-positive pathogen infection. Cell. 2018;175:1651–64. e1614.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhao Y, Yang J, Shi J, Gong Y, Lu Q, Xu H, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature. 2011;477:596–600.

CAS  PubMed  Article  Google Scholar 

Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey D, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Coll RC, Robertson A, Chae J, Higgins S, Muñoz-Planillo R, Inserra M, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–55.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, et al. K(+) efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria. Immunity. 2016;45:761–73.

PubMed  Article  CAS  Google Scholar 

Xu Z, Chen ZM, Wu X, Zhang L, Cao Y & Zhou P. Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation. Front Immunol. 2020;11:609441.

Dudem S, Sergeant GP, Thornbury KD & Hollywood MA. Calcium-activated K(+) Channels (K(Ca)) and therapeutic implications. Handb Exp Pharmacol. 2021;267:379–416.

Nielsen OH, New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3.

Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.